Demant Future Growth

Future criteria checks 4/6

Demant is forecast to grow earnings and revenue by 12.4% and 6.1% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 28.1% in 3 years.

Key information

12.4%

Earnings growth rate

15.5%

EPS growth rate

Medical Equipment earnings growth	18.6%
Revenue growth rate	6.1%
Future return on equity	28.1%
Analyst coverage	Good
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

WBAG:DEMA - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	25,845	3,453	3,460	4,656	15
12/31/2025	24,035	3,075	3,148	4,202	17
12/31/2024	22,427	2,490	2,699	3,671	15
6/30/2024	22,836	2,535	2,836	3,644	N/A
3/31/2024	22,640	2,544	3,130	3,957	N/A
12/31/2023	22,443	2,552	3,424	4,270	N/A
9/30/2023	21,442	2,577	2,932	3,815	N/A
6/30/2023	20,902	2,488	2,462	3,387	N/A
3/31/2023	20,304	2,381	1,954	2,878	N/A
12/31/2022	19,705	2,274	1,445	2,369	N/A
9/30/2022	19,181	2,460	1,581	2,472	N/A
6/30/2022	18,656	2,645	1,716	2,575	N/A
3/31/2022	18,281	2,671	2,135	2,927	N/A
12/31/2021	17,905	2,696	2,553	3,279	N/A
9/30/2021	17,521	2,453	2,663	3,341	N/A
6/30/2021	17,137	2,209	2,772	3,403	N/A
3/31/2021	15,803	1,665	2,356	3,012	N/A
12/31/2020	14,469	1,121	1,940	2,621	N/A
9/30/2020	14,072	970	1,507	2,226	N/A
6/30/2020	13,674	818	1,073	1,831	N/A
3/31/2020	14,310	1,140	1,228	1,990	N/A
12/31/2019	14,946	1,462	1,383	2,149	N/A
9/30/2019	14,728	1,579	1,218	1,942	N/A
6/30/2019	14,510	1,695	1,052	1,734	N/A
3/31/2019	14,224	1,759	1,059	1,709	N/A
12/31/2018	13,937	1,823	1,065	1,683	N/A
9/30/2018	13,699	1,836	1,268	1,833	N/A
6/30/2018	13,461	1,849	1,471	1,982	N/A
3/31/2018	13,325	1,802	N/A	1,927	N/A
12/31/2017	13,189	1,754	N/A	1,872	N/A
9/30/2017	12,943	1,689	N/A	1,855	N/A
6/30/2017	12,697	1,624	N/A	1,837	N/A
3/31/2017	12,350	1,542	N/A	1,758	N/A
12/31/2016	12,002	1,459	N/A	1,679	N/A
9/30/2016	11,717	1,429	N/A	1,622	N/A
6/30/2016	11,432	1,399	N/A	1,565	N/A
3/31/2016	11,049	1,418	N/A	1,579	N/A
12/31/2015	10,665	1,436	N/A	1,592	N/A
9/30/2015	10,258	1,402	N/A	1,568	N/A
6/30/2015	9,850	1,367	N/A	1,544	N/A
3/31/2015	9,598	1,347	N/A	1,520	N/A
12/31/2014	9,346	1,326	N/A	1,495	N/A
9/30/2014	9,221	1,301	N/A	1,380	N/A
6/30/2014	9,095	1,275	N/A	1,265	N/A
3/31/2014	9,027	1,280	N/A	1,274	N/A
12/31/2013	8,959	1,285	N/A	1,282	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DEMA's forecast earnings growth (12.4% per year) is above the savings rate (1.4%).

Earnings vs Market: DEMA's earnings (12.4% per year) are forecast to grow faster than the Austrian market (9.1% per year).

High Growth Earnings: DEMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DEMA's revenue (6.1% per year) is forecast to grow faster than the Austrian market (0.7% per year).

High Growth Revenue: DEMA's revenue (6.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DEMA's Return on Equity is forecast to be high in 3 years time (28.1%)

Demant Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Demant A/S Updates Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2024

Demant A/S Provides Earnings Guidance for the Year 2023

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/Sreiterated Guidance for the Year 2021

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

First half 2024 earnings released: EPS: kr.6.18 (vs kr.6.14 in 1H 2023)

Demant A/S Updates Earnings Guidance for the Year 2024

Investor sentiment deteriorates as stock falls 16%

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Demant A/S Provides Earnings Guidance for the Year 2024

Now 21% undervalued

Full year 2023 earnings released: EPS: kr.11.43 (vs kr.10.06 in FY 2022)

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Now 20% undervalued

Demant A/S Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Now 20% undervalued

First half 2023 earnings released: EPS: kr.5.63 (vs kr.5.07 in 1H 2022)

Now 21% undervalued after recent price drop

Now 21% undervalued

Demant A/S Announces Executive Changes

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr.10.06 (vs kr.10.70 in FY 2021)

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Demant A/S Revises Earnings Guidance for the Full Year 2022

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Now 20% undervalued after recent price drop

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 21% undervalued after recent price drop

Demant A/S Announces Update on Voluntary Field Corrective Action

Demant A/Sreiterated Guidance for the Year 2021

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: €35.34

New 90-day high: €31.77

Demant Launches New Flagship Hearing aids

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies